| Q34795330 | A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma. |
| Q42832145 | A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro |
| Q44031846 | A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies. |
| Q34729529 | A phase I study of intravenous bryostatin 1 in patients with advanced cancer |
| Q43602593 | A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. |
| Q28141839 | A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker |
| Q45713414 | A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. |
| Q34642231 | Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. |
| Q38391089 | Angiogenic growth factor expression in benign and malignant vascular tumours |
| Q84384562 | Angiosarcoma |
| Q47122078 | Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update |
| Q45927391 | Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. |
| Q73121272 | Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer |
| Q36540914 | Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium |
| Q91816031 | Association analysis of driver-gene related genetic variants identified novel lung cancer susceptibility loci with 20,871 lung cancer cases and 15,971 controls |
| Q69896760 | Back pain and testicular germ cell tumours |
| Q35780792 | Bone-targeted agents in the treatment of lung cancer. |
| Q39600665 | Breast milk in Botswana: cream and vitamin C contents |
| Q26999715 | CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis |
| Q71679482 | Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer |
| Q34425758 | Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium |
| Q38372645 | Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial |
| Q41380574 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial |
| Q93788023 | Cytokine Therapy |
| Q30684593 | Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors |
| Q59853934 | Detection of small cell lung cancer by RT-PCR for neuropeptides, neuropeptide receptors, or a splice variant of the neuron restrictive silencer factor |
| Q41759937 | Dose intensity in small cell lung cancer. |
| Q33356757 | Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells |
| Q72781291 | Effects of erythropoietin on mobilisation of haemopoietic progenitor cells |
| Q62583131 | Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis |
| Q87288646 | Eribulin in soft-tissue sarcoma |
| Q38737950 | Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. |
| Q58351991 | Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity |
| Q39087655 | First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. |
| Q36368641 | First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial |
| Q36620393 | Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes |
| Q97566958 | Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial |
| Q40040202 | Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial |
| Q37309498 | Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis |
| Q64064541 | Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development |
| Q47736284 | Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population |
| Q79896696 | Genomic tests: unreliable for cancer? A focus on circulating DNA and lung cancer |
| Q72651505 | Growth factors, antagonists and lung cancer |
| Q35214578 | Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. |
| Q58351997 | Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk |
| Q36243132 | Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium |
| Q39704322 | Lactate elimination in man: effects of lactate concentration and hepatic dysfunction |
| Q38730359 | Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes |
| Q74107156 | Lung cancer as the presenting feature of AIDS |
| Q49132660 | Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). |
| Q71663987 | Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood |
| Q34988594 | Neuroendocrine phenotype of small cell lung cancer |
| Q36253648 | New perspectives in lung cancer. 2. Growth factors and lung cancer |
| Q33778268 | Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study |
| Q34961717 | Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. |
| Q37338005 | Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. |
| Q85448625 | Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study |
| Q37155636 | Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers |
| Q83238056 | Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours |
| Q69403085 | Pericardial effusion complicating breast cancer |
| Q71602641 | Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis |
| Q33557729 | Persistent back pain due to malignant lymphadenopathy |
| Q34724640 | Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study |
| Q33376557 | Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
| Q36081960 | Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q48077813 | Quality of life, support and smoking in advanced lung cancer patients: a qualitative study. |
| Q46323227 | Raised serum urea predicts for early death in small cell lung cancer. |
| Q40175697 | Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. |
| Q43273408 | Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer |
| Q36557454 | Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer |
| Q46471444 | Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer |
| Q51054343 | Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. |
| Q43056046 | Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour. |
| Q46459730 | Roles for USF-2 in lung cancer proliferation and bronchial carcinogenesis. |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q73616527 | Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium |
| Q59289408 | Suramin for breast and prostate cancer: A pilot study of intermittent short infusions without adaptive control |
| Q91251784 | The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial |
| Q40545360 | The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. |
| Q38976675 | The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC). |
| Q41053000 | The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey |
| Q70279833 | Totally implantable vascular access for long term chemotherapy |
| Q34596126 | Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. |
| Q39479191 | Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells |
| Q57306270 | Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing |
| Q24535413 | Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box |
| Q72266341 | Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC) |
| Q40796041 | Use of RT-PCR to detect co-expression of neuropeptides and their receptors in lung cancer. |
| Q31826613 | Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients |
| Q39061298 | Vascular-targeted agents for the treatment of angiosarcoma |
| Q72627279 | Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time |
| Q69757063 | Who treats cancer? |
| Q33560104 | [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro |